CA2979293C - Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) - Google Patents

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) Download PDF

Info

Publication number
CA2979293C
CA2979293C CA2979293A CA2979293A CA2979293C CA 2979293 C CA2979293 C CA 2979293C CA 2979293 A CA2979293 A CA 2979293A CA 2979293 A CA2979293 A CA 2979293A CA 2979293 C CA2979293 C CA 2979293C
Authority
CA
Canada
Prior art keywords
treatment
obesity
diabetes
type
pancreatic endocrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2979293A
Other languages
English (en)
French (fr)
Other versions
CA2979293A1 (en
Inventor
Timothy J. Kieffer
Jennifer E. BRUIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CCS Ventures Ltd
Original Assignee
CCS Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CCS Ventures Ltd filed Critical CCS Ventures Ltd
Publication of CA2979293A1 publication Critical patent/CA2979293A1/en
Application granted granted Critical
Publication of CA2979293C publication Critical patent/CA2979293C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2979293A 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) Active CA2979293C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131540P 2015-03-11 2015-03-11
US62/131,540 2015-03-11
PCT/CA2016/000072 WO2016141460A1 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Publications (2)

Publication Number Publication Date
CA2979293A1 CA2979293A1 (en) 2016-09-15
CA2979293C true CA2979293C (en) 2022-01-04

Family

ID=56879832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979293A Active CA2979293C (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Country Status (7)

Country Link
US (2) US10772917B2 (cg-RX-API-DMAC7.html)
EP (1) EP3268016B1 (cg-RX-API-DMAC7.html)
JP (1) JP6847044B2 (cg-RX-API-DMAC7.html)
CN (1) CN107530379A (cg-RX-API-DMAC7.html)
AU (1) AU2016228894B2 (cg-RX-API-DMAC7.html)
CA (1) CA2979293C (cg-RX-API-DMAC7.html)
WO (1) WO2016141460A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118641A1 (en) * 2017-12-12 2019-06-20 The Regents Of The University Of California Preservation of pancreatic islet grafts in the extrahepatic space
EP3741757B1 (en) 2018-01-18 2023-07-26 Daiichi Sankyo Company, Limited Dihydroindolizinone derivative
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CA3139294A1 (en) 2019-05-22 2020-11-26 The Cleveland Clinic Foundation Generating dorsal foregut, and anterior domain, endoderm cells
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
BR0213805A (pt) * 2001-11-09 2005-08-16 Artecel Sciences Inc Células estromais derivadas de tecido adiposo para diferenciação endócrina do pâncreas e usos das mesmas
EP1509087A4 (en) * 2002-05-24 2005-12-21 Waratah Pharmaceuticals Inc TREATMENT FOR DIABETES
WO2004023100A2 (en) * 2002-09-06 2004-03-18 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
PL1641914T3 (pl) 2003-06-27 2017-01-31 DePuy Synthes Products, Inc. Komórki pochodzące z poporodowej tkanki łożyska oraz sposoby uzyskiwania i zastosowania tych komórek
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
JP2006149380A (ja) * 2004-10-27 2006-06-15 Kobe Univ 遺伝子改変動物の新規用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
WO2008054716A2 (en) * 2006-10-31 2008-05-08 National Stem Cell Holding Inc. Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata
CN101588795A (zh) * 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
US20090280096A1 (en) * 2008-05-09 2009-11-12 Atsushi Kubo Pancreatic endocrine progenitor cells derived from pluripotent stem cells
NZ594044A (en) * 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
AU2010319921A1 (en) 2009-10-29 2012-05-17 Janssen Biotech Inc. Pluripotent stem cells
US9085757B2 (en) * 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
CN103052393B (zh) 2010-08-12 2017-11-14 詹森生物科技公司 用胰腺内分泌前体细胞治疗糖尿病
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Also Published As

Publication number Publication date
US20180055890A1 (en) 2018-03-01
WO2016141460A1 (en) 2016-09-15
EP3268016A1 (en) 2018-01-17
EP3268016B1 (en) 2021-04-28
US10772917B2 (en) 2020-09-15
CN107530379A (zh) 2018-01-02
AU2016228894B2 (en) 2021-03-04
AU2016228894A1 (en) 2017-11-02
JP6847044B2 (ja) 2021-03-24
EP3268016A4 (en) 2018-12-12
JP2018507889A (ja) 2018-03-22
US20210015872A1 (en) 2021-01-21
CA2979293A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
CA2979293C (en) Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
Rose et al. Metabolic control through glucocorticoid hormones: an update
JOP20200202A1 (ar) اجسام مضادة بشرية لمستقبل الجلوكاجون
Billy et al. Synchronisation and control of proliferation in cycling cell population models with age structure
MX2017011422A (es) Composiciones y metodos para inhibir la expresion del gen del factor xii.
MX360824B (es) Una combinación para inducir la formación de células beta de células de mamífero y uso de la misma.
MX2016003945A (es) Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias.
PH12017501217A1 (en) Methods of treating retinal diseases
MX381766B (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia.
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
EP4497472A3 (en) Production of fully functional mature beta cells from human pancreatic progenitors
PH12013500199A1 (en) Treatment of diabetes with pancreatic endocrine precursor cells
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
MX2009012969A (es) Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
WO2015106296A8 (en) Enolase 1 (eno1) compositions and uses thereof
WO2017059177A3 (en) Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
PH12014500596A1 (en) Plant steroids and uses thereof
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
WO2014100816A3 (en) Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
MX2023015068A (es) Analogo de glucagon y uso medico del mismo.
友久 In-home occupational therapy for a patient with stage IV lung cancer: changes in quality of life and analysis of causes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210211